Award
National Institute of Neurological Disorders and Stroke 1R44NS143576-01
Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy
Recipient
RESPIRERX PHARMACEUTICALS INC.
Award Amount
$1,499,869.00
Ceiling
$1,499,869.00
Awarded
September 23, 2025
Identifier
1R44NS143576-01
RespireRx Pharmaceuticals Inc. received funding to develop KRM-II-81, a novel GABAA receptor potentiator aimed at improving epilepsy treatment by enhancing seizure control and reducing side effects. The project includes manufacturing process development, pharmacokinetics evaluation, toxicology studies, and preparation for human clinical trials.
Description
This project focuses on developing and scaling up the synthesis of KRM-II-81, evaluating its pharmacokinetics and safety in preclinical models, and preparing for IND submission to facilitate clinical trials. Success will position RespireRx to initiate Phase I trials and potentially introduce a breakthrough therapy for pharmacoresistant epilepsy.